Sage Spurns Biogen, Turns Attention To Strategic Review

Proposed Deal’s Value Seen As Too Low

 
• By Mandy Jackson
  
Sage is reviewing strategic alternatives rather than accepting Biogen's buyout bid (Shutterstock)

More from Deals

More from Scrip